DSM-Firmenich weekly buyback progress, shares compared with European peers

By Julia Schmitt, Sector & Peer Group desk. Reviewed prior to publication on 2026-06-26, 16:15.

DSM-Firmenich (CH1216478797) remains active on its share repurchase program in Zurich. A recent weekly progress update highlights ongoing buybacks, while the shares trade alongside chemicals and specialty ingredients peers on SIX Swiss Exchange.Amana app data on DSFIR

What recent updates show

According to a recent progress note, DSM-Firmenich continues a share repurchase program designed to cover share plans and reduce capital, with weekly activity reported against a defined authorization.TradingView summary of DSM-Firmenich buybacks The program runs alongside the company’s listing on SIX Swiss Exchange, where the DSFIR ticker quotes in Swiss francs.

In parallel, sector investors still discuss DSM-Firmenich’s June announcement that the U.S. Food and Drug Administration approved bemotrizinol under the brand name PARSOL Shield, a new sunscreen active ingredient for the U.S. market.Globenewswire press release on PARSOL Shield The approval came on June 10, 2026 and marked the first new sunscreen active cleared in the U.S. in more than 25 years under modernized GRASE and MUsT guidelines.

How the stock sits in its sector

DSM-Firmenich operates in the broader European chemicals and ingredients space, where peers such as BASF and Clariant also trade on continental exchanges and compete for investor attention.Reuters sector overview for European chemicals In recent sector roundups, specialty ingredients names have been discussed for their defensive earnings qualities and exposure to consumer-facing end markets.

Analyst commentary on the segment highlights how diversified exposure across nutrition, health and beauty can support earnings resilience versus more cyclical bulk chemicals, with DSM-Firmenich often cited as a key player in this specialty cluster.UBS analysis of European chemicals and specialties The buyback program and the PARSOL Shield approval both feed into the equity story, where capital returns and innovation contribute to longer-term positioning.

The products behind the stock

DSM-Firmenich’s Beauty & Care unit markets PARSOL Shield, a bemotrizinol-based sunscreen active ingredient positioned for high UVA and UVB protection in modern sun care formulations.DSM-Firmenich product page for PARSOL Shield The company also supplies a wide range of nutrition, health and fragrance ingredients that underpin consumer products in food, dietary supplements and personal care.

Where the shares trade today

The DSM-Firmenich shares (CH1216478797) trade on SIX Swiss Exchange under the ticker DSFIR; the latest verifiable quote around 80.08 Swiss francs comes from a June 2026 snapshot of Zurich trading.Amana quote overview for DSFIR

Disclaimer: This article is for information purposes only and does not constitute investment advice, a recommendation to buy or sell securities, or a solicitation of any transaction. All data are based on sources deemed reliable at the time of publication, but accuracy and completeness cannot be guaranteed.